Skip to NavigationSkip to content

Bayer's Eylea shows strong vision benefits across two regimens in post-marketing study

Published on 05/02/20 at 12:19pm

Bayer has pulled back the curtain on new Phase 4 data for Eylea (aflibercept), revealing strong findings in the treatment of wet age-related macular degeneration (AMD) via two different Treat and Extend (T&E) dosing regimens.

The trial examined 246 participants, treating them with Eylea for three consecutive monthly doses before a bimonthly injection interval. After 16 weeks of treatment, the participants were randomised to either a two-week or four-week interval-adjusted T&E dosing regimen.

After 52 weeks, a change of 9.0 and 8.4 from baseline in best corrected visual acuity (BCVA) was recorded in the two-week group and the four-week group respectively, as measured by Early Treatment Diabetic Retinopathy Study (ETDRS). These effects continued up to 96 weeks of treatment, alongside an average improvement of 7.6 letters and 6.1 letters in the two-week and four-week groups.

There are around 39,800 new cases of wet AMD each year in the UK, and symptoms of the disease can worsen into old age, potentially culminating in vision loss.

“Allowing greater flexibility of aflibercept injections in year one, and extension to intervals up to 16 weeks could provide significant benefits for patients and their carers, including fewer medical appointments, reduced waiting lists and an improvement in the overall burden associated with this treatment experience,” said Dr Jackie Napier, Medical Director of Ophthalmology at Bayer. “As well as ensuring that patients receive the level of care that suits the need of each individual, these results could contribute to relieving capacity pressures and treatment costs for overstretched NHS services”. 

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches